e-Therapeutics plc Provides Update On ETS2101 Phase I Trial In Brain Cancer
1/7/2014 9:08:35 AM
OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--e-Therapeutics plc today announces that the investigator-led phase I trial of ETS2101 in brain cancer will continue into 2014. Five dose escalation steps have been completed without any drug-related serious adverse events and the investigator therefore intends to enrol further patients at higher dose levels.
Help employers find you! Check out all the jobs and post your resume.
comments powered by